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Abstract
Background: Low plasma concentration of adiponectin, a hormone-like peptide secreted by
adipose tissue, is detected in obesity and in coronary artery disease. The aim of the study was to
assess the impact of obesity on adiponectin and the relation of adiponectin to the anthropometric
parameters and cardiovascular risk factors in men with acute myocardial infarction.
Methods: Two groups of patients with first acute myocardial infarction were analyzed:
40 obese and 40 non-obese men. Waist and hip circumferences and waist-to-hip ratio, C-reactive
protein (CRP), uric acid, fasting glucose, lipid profile and adiponectin were measured.
Results: Mean level of adiponectin was significantly lower in obese than non-obese patients
(6.80 mg/ml ± 4.31 vs. 11.18 mg/ml ± 7.19; p < 0.01). Adiponectin levels correlated negatively
with all anthropometric measurements, the most significantly with waist circumference, with
systolic blood pressure, fasting glucose, triglyceride levels, CRP, uric acid and positively with
age and HDL-cholesterol. Adiponectin level was significantly associated with HDL-cholesterol,
waist circumference and with trigliceryde levels and these independent variables explained
39% of the plasma adiponectin variability.
Conclusions: In patients with acute myocardial infarction obesity is related to decreased
adiponectin. Low adiponectin level is associated with atherogenic lipid profile and higher levels
of inflammatory markers. (Cardiol J 2007; 14: 29–36)
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Introduction
Excess body fat, particularly abdominal adipos-
ity, not only carries a cluster of cardiovascular risk
factors [1] but is itself an independent cardiovas-
cular risk factor [2–4]. Obesity in patients with
established coronary artery disease worsens the
prognosis [5]. It has been revealed that body mass
index (BMI) is associated with acute coronary syn-
dromes [6, 7]. Recent evidence suggests that adipose
tissue is both a storage site for fat and an active en-
docrine and paracrine system. It secretes adipokines,
hormone-like peptides which have an impact on glu-
cose and lipid metabolism, the inflammatory proc-
ess and other bioactivities [8–10]. Adiponectin is
regarded as a protective adipokine associated with
lower risk of myocardial infarction [11]. A wide range
of adiponectin levels (1.9–17.0 mg/ml) has been
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detected in healthy subjects [12]. Decreased plas-
ma adiponectin concentration is detected in obesity
[12, 13] and it is associated with cardiovascular risk
factors such as insulin resistance, impaired glucose
metabolism, arterial hypertension, decreased blood
concentration of high-density lipoprotein cholester-
ol (HDL-CH) and increased concentration of trigly-
cerides (TG) [14–17]. Adiponectin has an impact on
the endothelial function, mostly by the modulation
of endothelial inflammatory reaction [18, 19]. Hy-
poadiponectinaemia is detected in patients with
coronary artery disease [4, 20] and is related to
clinical instability [21]. Studies are currently be-
ing carried out in order to elucidate the precise
mechanism linking adiponectin and vascular dis-
ease, including endothelial dysfunction, athero-
sclerosis and restenotic change after balloon an-
gioplasty [22–25]. The results may subsequently
lead to preventive measures and eventually to
a specific treatment.
The aim of the study was to assess the impact
of obesity on adiponectin and the relationship be-
tween its concentration and the anthropometric
parameters and cardiovascular risk factors in men




From the cohort of patients with first acute
myocardial infarction which had been successfully
treated with primary coronary intervention (TIMI
flow grade 3, residual stenosis < 30%) 40 obese
men age £ 65 years, who admitted to being obese
for at least 5 years, were selected for the study
group. A further 40 non-obese men, matched to the
obese group for age and localisation ofthe myocar-
dial infarction, were included in the study as a con-
trol group. Our study was designed for males in
order to avoid the impact of sex on the results. It
has been reported that there are sex-related differ-
ences in the location of adipose tissue, the number
of fat cells and fat-cell size and plasma adiponectin
concentrations [16, 26, 27].
Insulin therapy before blood sampling for adi-
ponectin measurement was considered a criterion
for exclusion. Additional exclusion criteria were
applied owing to the unreported in this study require-
ments for the acquisition of echocardiographic
parameters. These conditions were atrial fibrilla-
tion, atrio-ventricular or bundle branch block, tem-
porary or permanent stimulation and significant
valvular heart disease.
Anthropometric measurements
clinical definitions and treatment
Diagnosis of acute myocardial infarction was
based on the clinical symptoms, electrocardiographic
signs and elevation of myocardial necrotic markers.
All patients received aspirin and those who under-
went stenting were concomitantly treated with an
additional antiplatelet agent. Heparin was infused
during the procedure. Glycoprotein IIb/IIIa inhibi-
tor was administered at the physician’s discretion.
Body mass index calculated as the body weight
divided by the square of the height (kg/m2) was used
as a marker of obesity. Weight and height were
measured on the third or fourth day after admission
while the subjects were fasting and wearing only
their undergarments. Patients were designated as
obese where BMI exceeded 30 kg/m2 and were con-
sidered non-obese where BMI was below 25 kg/m2.
Waist circumference, a measure of subcutaneous
plus visceral fat, was measured at the widest diame-
ter between the xiphoid process of the sternum and
the iliac crest. Hip circumference, representing sub-
cutaneous fat alone, was measured at the widest di-
ameter over the greater trochanters. Waist-to-hip
ratio was than calculated. Systolic and diastolic blood
pressure was measured before blood sampling.
The study was approved by the Internal
Ethics Committee of Medical University of Łódź,
and each patient gave informed consent.
Laboratory measurements
Along with several analyses performed from
the samples of blood taken on admission to the hos-
pital, C-reactive protein (CRP) and uric acid were
assessed. Fasting glucose, lipid profile, and adi-
ponectin were determined from blood drawn on the
following day. Plasma TG and total cholesterol
(TCH) were measured by enzymatic analytical
chemistry. The HDL-cholesterol was precipitated
using dextran-sulphate and measured enzymatically.
The low-density lipoprotein cholesterol (LDL-CH)
was calculated using the Friedewald equation: LDL-
-CH = TCH – (TG/5) – HDL-CH. Impaired lipid me-
tabolism was diagnosed if at least one of the follow-
ing disorders was present: hypercholesterolemia
(TCH > 200 mg/dl), hypertriglicerydemia
(TG > 150 mg/dl), high LDL-CH (LDL-CH > 100 mg/dl)
or low HDL-CH (HDL-CH < 40 mg/dl). Plasma
glucose concentrations were measured with the
oxidise method, uric acid with the colorimetric
method and CRP concentrations with an immuno-
tubidimetric assay.
Plasma samples for adiponectin concentration
measurements were frozen at –70° until analysis with
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a sandwich enzyme-linked immunosorbent assay
(ELISA).
Statistical analysis
Continuous data were expressed as mean ±
± standard derivation. Variables were log-trans-
formed before statistical analysis if necessary. Com-
parisons between the obese and non-obese group
were analysed with Student’s t-test or the Mann-
-Whitney test, as appropriate. Categorical variables
were presented as the number and percentage of
patients and comparisons between the two groups
were analysed with the c2 test.
The relationship between adiponectin concen-
tration and the analyzed parameters (clinical, an-
thropometric and biochemical) were examined us-
ing Pearson’s or Spearman’s correlation coefficient,
as appropriate. A multiple stepwise regression analy-
sis was performed to evaluate the independent con-
tribution of anthropometric parameters (BMI, waste
circumference and waist-to-hip ratio) to the vari-
ance of adiponectin.
The univariate regression analysis included
age, systolic and diastolic blood pressure, waist cir-
cumference (the best anthropometric predictor of
adiponectin distribution), fasting glucose, TCH,
HDL-CH, TG, LDL-CH, CRP and uric acid. Inde-
pendent variables that correlated with adiponectin
in the univariate analysis were included in the mul-
tiple stepwise regression model. The results are
presented as relative risk (RR) and 95% confidence
intervals (CI). A p value of < 0.05 was considered
to be statistically significant.
Results
The clinical characteristics and anthropomet-
ric measurements of the study population are shown
in Table 1. The incidence of most cardiovascular
risk factors (hypertension, diabetes, smoking and
hypercholesterolemia) was similar in the two groups.
A significant difference between groups was ob-
served only in the proportion of patients with HDL-
-CH < 40 mg/dl (37.5% vs. 12.5%, p < 0.01) and
TG > 150 mg/dl (60% vs. 32.5%, p < 0.05). The val-
ue of systolic blood pressure was significantly higher
in obese than in non-obese patients (124.1 mm Hg ±
± 9.32 vs. 119.0 mm Hg ± 13.2; p < 0.05). All the
assessed anthropometric measurements (BMI,
waist circumference and waist-to-hip ratio) were
also significantly higher in obese than non-
-obese group (p < 0.0001). Glycoprotein IIb/IIIa in-
hibitor was administered to a similar proportion of
patients from each group. Pharmacological treatment
with aspirin, clopidogrel, statins, beta-blockers, in-
hibitors of angiotensin II, nitrates and diuretics was
similar in the two groups.
Biochemical data in obese and non-obese pa-
tients are summarised in Table 2. In obese patients
the values of the following parameters were signifi-
cantly higher than in non-obese: TG (161.3 mg/dl ±
± 59.8 vs. 132.9 mg/dl ± 52.1; p < 0.01), fasting
glucose (110.1 mg/dl ± 14.5 vs. 94.8 mg/dl ± 10.3,
p < 0.001) and CRP (7.95 mg/dl ± 7.29 vs. 4.25 mg/dl ±
± 4.85, p < 0.01), whereas HDL-CH levels were
lower (45.6 mg/dl ± 11.9 vs. 51.6 mg/dl ± 12.3,
p < 0.05).
Table 1. The clinical characteristics and anthropometric measurements of the study groups.
Obese (n = 40) Non-obese (n = 40) p
Age 53.6±7.39 54.4±6.62 NS
Hypertension 25 (62.5%) 18 (45%) NS
Systolic blood pressure [mm Hg] 124.1±9.32 119.0±13.2 < 0.05
Diastolic blood pressure [mm Hg] 75.5±6.18 73.1±8.37 NS
Diabetes mellitus 11 (27.5%) 7 (17.5%) NS
Total cholesterol > 200 mg/dl 27 (67.5%) 26 (65%) NS
HDL-cholesterol < 40 mg/dl 15 (37.5%) 5 (12.5%) < 0.01
Triglycerides > 150 mg/dl 24 (60%) 13 (32.5%) < 0.05
LDL-cholesterol > 100 mg/dl 36 (90%) 34 (85%) NS
Smoking 25 (62.5%) 27 (67.5%) NS
Body mass index 32.2±1.96 23.8±1.40 < 0.0001
Waist circumference [cm] 111.9±7.52 88.1±7.09 < 0.0001
Hip circumference [cm] 108.3±6.73 91.4±7.67 < 0.0001
Waist-to-hip ratio 1.03±0.05 0.96±0.3 < 0.001
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Mean adiponectin level was significantly low-
er in obese than non-obese group (6.80 mg/ml ± 4.31
vs. 11.18 mg/ml ± 7.19; p < 0.01) (Fig. 1).
The association of adiponectin with anthropo-
metric measurements is shown in Figure 2. Adi-
ponectin was negatively correlated with all the
anthropometric measurements, with the closest
correlation observed for waist circumference (r = –0.52,
p < 0.0001). Moreover, multiple stepwise regres-
sion analysis revealed that waist circumference was
the only independent predictor of adiponectin (RR =
= –0.209; 95%CI –0.229 to –0.120, p < 0.0001) and
could explain 21% of the variation in adiponectin in
a model including BMI, waist circumference and
waist-to-hip ratio. In the study group as a whole
a positive correlation was detected between adi-
ponectin and HDL-CH (r = 0.57, p < 0.0001) and
age (r = 0.23, p < 0.05), whereas a negative corre-
lation was observed between adiponectin and systo-
lic blood pressure (r = –0.33, p < 0.01), fasting glu-
cose (r = –0.47, p < 0.0001), TG (r = –0.49,
p < 0.0001), CRP (r = –0.45, p < 0.0001) and uric
acid (r = –0.37, p < 0.001) (Table 3). Adiponectin
correlated with lipid parameters (HDL-CH and TG)
more closely in obese than in non-obese group. The


































































































Table 2. Biochemical parameters in the study groups.
Obese (n = 40) Non-obese (n = 40) p
Fasting glucose [mg/dl] 110.1±14.5 94.8±10.3 < 0.001
Total cholesterol [mg/dl] 224.2±44.0 216.7±40.1 NS
HDL-cholesterol [mg/dl] 45.6±11.9 51.6±12.3 < 0.05
Triglycerides [mg/dl] 161.3±59.8 132.9±52.1 < 0.01
LDL-cholesterol [mg/dl] 146.3±43.1 138.4±42.5 NS
C-reactive protein [mg/dl] 7.95±7.29 4.25±4.84 < 0.01
Uric acid [mg/dl] 6.11±1.48 5.66±1.47 NS
Figure 1. The mean value ot plasma adiponectin con-
centration in the study groups.
Figure 2. Correlation between plasma adiponectin con-
centration and anthropometric measurements.
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between adiponectin and fasting glucose was ob-
served only in the obese group (Table 3).
As shown in Table 4, univariate regression analy-
sis revealed a relation between adiponectin and systo-
lic blood pressure, waist circumference, fasting glucose,
HDL-CH, TG, CRP and uric acid. In the multiple step-
wise regression analysis, adiponectin concentration
was independently associated with HDL-CH, waist
circumference and TG and these variabies explained
39% of adiponectin variability (Table 5).
Discussion
Abdominal obesity is an element of the meta-
bolic syndrome, a c1uster of proatherogenic meta-
bolic disorders. There is growing evidence of an
association between low adiponectin and the meta-
bolic and cardiovascular complications of obesity.
This is why it has been suggested that adiponectin
could be a link between excess adiposity and
atherosclerotic vascular disease.
Table 3. Correlation between plasma adiponectin concentration and clinical and biochemical parameters.
All patients Obese Non-obese
Age r = 0.23 (p < 0.05) r = 0.29 (NS) r = 0.17 (NS)
Systolic blood pressure r = –0.33 (p < 0.01) r = –0.29 (NS) r = 0.0004 (NS)
Diastolic blood pressure  r = –0.11 (N S) r = –0.21 (NS) r = –0.09 (NS)
Fasting glucose r = –0.47 (p < 0.0001) r = –0.46 (p < 0.0001) r = –0.22 (NS)
Total cholesterol r = 0.09 (NS) r = 0.25 (NS) r = 0.03 (NS)
HDL-cholesterol r = 0.57 (p < 0.0001) r = 0.67 (p < 0.0001) r = 0.42 (p < 0.0001)
Triglycerides r = –0.49 (p < 0.0001) r = –0.51 (p < 0.001) r = –0.39 (p < 0.05)
LDL-cholesterol r = 0.06 (NS) r = 0.21 (NS) r = 0.006 (NS)
C-reactive protein r = –0.45 (p < 0.0001) r = –0.55 (p < 0.0001) r = –0.2 (NS)
Uric acid r = –0.37 (p < 0.001) r = –0.33 (p < 0.05) r = –0.33 (p < 0.05)
Table 4. Univariate regression analysis for plasma adiponectin concentration.
Relative –95% confidence +95% confidence p
risk intervals intervals
 Age 0.1769 –0.02233 0.376179 0.081
 Systolic blood pressure –0.143 –0.26011 –0.02592 0.0173
 Diastolic blood pressure –0.075 –0.26579 0.115664 0.4356
 Waist circumference –0.2092 –0.29889 –0.11964 0.0001
 Fasting glucose –0.1654 –0.25435 –0.07652 0.0003
 Total cholesterol 0.0048 –0.0289 0.038573 0.7759
 HDL-cholesterol 0.2431 0.143146 0.343173 0.0001
 Triglycerides –0.0455 –0.06796 –0.02317 0.0001
 LDL-cholesterol 0.0006 –0.03257 0.03382 0.9702
 C-reactive protein –0.3475 –0.55412 –0.14104 0.0012
 Uric acid –1.3693 –2.2751 –0.46363 0.0035
Table 5. The final model of multiple stepwise regression analysis for plasma adiponectin concentration.
Relative –95% confidence +95% confidence p
risk intervals intervals
HDL-cholesterol 0.1493 0.0500 0.2486 0.0037
Waist circumference –0.1371 –0.2233 –0.0510 0.0021
Triglycerides –0.0282 –0.0488 –0.0075 0.0080
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In this study we have confirmed that in patients
with acute myocardial infarction, similary as it has
been reported in previous studies in healthy sub-
jects and patients with various stages of coronary
artery disease, adiponectin is significantly lower in
obese than in non-obese patients and decreased
plasma adiponectin levels are more often observed
in the former than in the latter [11–13, 15, 16, 20, 28].
Adiponectin has been shown in vitro to be se-
creted particularly from the human visceral adipose
tissue [29] and its plasma concentration is influ-
enced to a greater extent by visceral than by sub-
cutaneous adipose tissue [30, 31]. With the aid of
computed tomography waist circumference was
identified as the best surrogate of visceral adiposi-
ty [32]. In our study, although all anthropometric pa-
rameters were negatively correlated with adiponectin,
the strongest correlation was observed for waist cir-
cumference, and multiple regression analysis revealed
that waist circumference was the only independent
anthropometric predictor of adiponectin level and could
explain 21% of adiponectin variation. Some other au-
thors have made different observations. Steiger et al.
[28] revealed that adiponectin correlates negatively
with waist-to-hip ratio but not with either waist cir-
cumference or hip circumference. Waist-to-hip ra-
tio was found to be a better screening measure for
cardiovascular risk factors than other anthropomet-
ric indicators by Esmaillzadeh et al. [33].
In the group of patients studied here we ob-
served that adiponectin increased with age (r = 0.23,
p < 0.001). This is in agreement with other authors
[16, 20] and it has been suggested that androgens
may inhibit adiponectin production [26]. The exact
effect of androgens on adiponectin is not known. On
the grounds of the in vitro studies it has been sug-
gested that testosterone may sequester a coactiva-
tor ARA70, common to the androgen receptor and
the peroxisome proliferator-activated receptor gam-
ma 1 (PPARg). Such competition may result in the
reduced expression of PPARg-regulated genes such
as adiponectin [34].
Several authors have shown the association be-
tween low adiponectin plasma concentration and the
atherogenic lipoprotein profile. We have revealed
a significant difference in adiponectin concentra-
tions as well as in HDL-CH and TG between the
groups of obese and non-obese patients. A signifi-
cant positive correlation, between adiponectin and
HDL-CH (r = 0.57, p < 0.0001) and a lesser nega-
tive correlation between adiponectin and TG
(r = –0.49, p < 0.0001) were revealed in our group
of patients. This observation is in agreement with
the results of previous studies performed in Euro-
pean, American and Japanese populations of healthy
individuals [15, 16, 30], patients with coronary ar-
tery disease [20] and subjects with obesity [35] and
diabetes [36]. Moreover, our observation [15, 35, 37]
that the contribution of HDL-CH and TG to the
variance of adiponectin is independent of age and
BMI is similar to that put forward by other au-
thors.
It has been suggested that the association of
high adiponectin with high HDL-CH and low TG
could be explained by a direct insulin-sensitising
effect of adiponectin on hepatic and muscle lipopro-
tein metabolism [37]. The negative correlation be-
tween adiponectin and uric acid revealed in our
study (r = –0.37, p < 0.001) is stronger than in the
male subgroup in the study by Yamamoto et al.
(r = –0.265, p < 0.0001) [15].
Recent studies have established the fundamen-
tal role of inflammation in mediating all stages of
atherosclerosis [19]. CRP is not only a marker of
the chronic inflammatory process but also a mole-
cule known to promote atherogenesis [38]. It has
been suggested that in patients with diabetes or at
higher risk of developing diabetes adiponectin is
involved in the modulation of inflammation, in part
through the underlying association with obesity
[36]. In our study CRP was significantly higher in
the obese patient group than in control group and,
in keeping with prior data [39, 40], adiponectin nega-
tively correlated with CRP. We suggest that
a strong direct association of adiponectin with CRP
in patients with acute myocardial infarction could
possibly be explained by the acute state of inflam-
mation underlying plaque rupture and the adhesion
of adiponectin to injured vascular walls, a process
described by Okamaoto et al. [41].
Study limitations
The time from the onset of acute myocardial
infarction to the blood sampling for adiponectin meas-
urements differed in individual patients by between
24 and 72 hours. Serial analysis of adiponectin in the
course of acute myocardial infarction performed by
Kojima et al. [39] showed that adiponectin significant-
ly declines during the initial 24 hours of acute myo-
cardial infarction but is relatively stable by the fol-
lowing 48 hours and then rises until the seventh day
of acute myocardial infarction, although it does not
reach the values assessed at admission.
Since plasma insulin levels were not available
in our data set, we were not able to examine the
impact of this potential intermediate variable.
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Conclusions
1. In patients with acute myocardial infarction
obesity is related to decreased plasma adi-
ponectin concentration.
2. Waist circumference is a better predictor of
plasma adiponectin concentration than body
mass index and waist-to-hip ratio.
3. Low adiponectin plasma concentration is asso-
ciated with atherogenic lipid profile and in-
creased inflammatory reaction.
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